ADC Therapeutics SA

ADCT Healthcare Biotechnology

ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.

1.41 0.08 −5.37%
Market cap
$190.2M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
5/9
Altman Z
−6.67
Beneish M
−2.09
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 5 3 2
ROE
81.41% 73.43% 60.27% 45.35%
ROA
(52.26%) (44.22%) (48.57%) (32.25%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(74.16%) (60.39%) (65.50%) (55.26%)
Average Days of Receivables
111.22 130.63 143.12 128.58
Free Cash Flow per Share
(0.97) (1.11) (0.74) (0.66)
Free Cash Flow
(132.26) (140.78) (113.92) (101.64)
Capital Expenditures
(0.35) 0.40 0.63 0.63
Other line items
Cash ROIC
(118.34%) (73.72%) (87.43%) (94.53%)
Accounts Receivable Turnover
3.20 3.29 2.52 2.94
Accounts Payable Turnover
0.49 0.43 0.70 0.79
Inventory Turnover
0.32 1.80 0.66 0.78
Average Days of Payables
541.76 577.59 262.88 525.41
Days of Inventory on Hand
1,203.90 263.39 237.11 203.07
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
150.14% 127.84% 119.93% 103.32%
Selling, General and Administrative Expense of Revenue
105.53% 98.25% 103.60% 107.22%
Share Based Compensation of Revenue
10.43% 8.49% 8.75% 12.14%
Interest Coverage
(2.69) (2.35) (2.29) (1.90)
Operating CF/Net income
0.79 0.99 0.84 1.06
Depreciation/Fixed assets
0.00 0.00 0.00 —
Capex/Depreciation
(0.08) 0.11 0.20 0.00
Revenue per Share
0.55 0.64 0.51 0.51
Operating CF per Share
(0.97) (1.11) (0.74) (0.66)
Capex per Share
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 (0.01) (0.01)

Fold the line items

Columns are period end dates